After Protagonist Therapeutics (PTGX) shared extended follow-up data from the Phase 2b ANTHEM-UC study of icotrokinra in ulcerative colitis at the ACG 2025 meeting, Clear Street said the firm sees “unmatched commercial promise” for the drug. These “consistent and durable results” underpin Johnson & Johnson’s (JNJ) progression of icotrokinra into a Phase 3 UC trial and a Phase 2/3 Crohn’s study, adds the analyst, who keeps a Buy rating and $74 price target on Protagonist shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics announces icotrokinra data in UC, plaque PsO
- 3 Stocks with a Flawless 10 Smart Score and Strong Buy Consensus
- Protagonist Therapeutics price target raised to $96 from $72 at Citi
- Protagonist Therapeutics price target raised to $112 from $72 at BMO Capital
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!